USD 7.36
(-1.6%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 56.49 Million USD | -35.93% |
2022 | 88.17 Million USD | 59.62% |
2021 | 55.24 Million USD | 32.75% |
2020 | 41.61 Million USD | 33.78% |
2019 | 31.1 Million USD | -91.2% |
2018 | 353.36 Million USD | -14.05% |
2017 | 411.14 Million USD | 530.29% |
2016 | 65.23 Million USD | 78.93% |
2015 | 36.45 Million USD | 47.95% |
2014 | 24.64 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 53.62 Million USD | -5.1% |
2024 Q2 | 53.89 Million USD | 0.51% |
2023 Q1 | 88.36 Million USD | 0.21% |
2023 Q2 | 69.74 Million USD | -21.07% |
2023 FY | 56.49 Million USD | -35.93% |
2023 Q4 | 56.49 Million USD | 16.39% |
2023 Q3 | 48.54 Million USD | -30.39% |
2022 Q2 | 78.7 Million USD | -0.96% |
2022 Q1 | 79.46 Million USD | 43.85% |
2022 Q4 | 88.17 Million USD | 7.59% |
2022 Q3 | 81.96 Million USD | 4.14% |
2022 FY | 88.17 Million USD | 59.62% |
2021 Q1 | - USD | -100.0% |
2021 Q2 | 73.51 Million USD | 0.0% |
2021 Q3 | 100.76 Million USD | 37.07% |
2021 Q4 | 55.24 Million USD | -45.18% |
2021 FY | 55.24 Million USD | 32.75% |
2020 Q4 | 41.61 Million USD | 0.0% |
2020 FY | 41.61 Million USD | 33.78% |
2020 Q1 | - USD | 0.0% |
2019 Q2 | 381.71 Million USD | -1.36% |
2019 FY | 31.1 Million USD | -91.2% |
2019 Q3 | 421.76 Million USD | 10.49% |
2019 Q1 | 386.98 Million USD | 9.51% |
2018 Q2 | 374.99 Million USD | -0.79% |
2018 Q3 | 356.07 Million USD | -5.05% |
2018 Q4 | 353.36 Million USD | -0.76% |
2018 FY | 353.36 Million USD | -14.05% |
2018 Q1 | 377.98 Million USD | -8.07% |
2017 Q3 | 475.72 Million USD | 41.85% |
2017 Q2 | 335.37 Million USD | 561.82% |
2017 Q1 | 50.67 Million USD | -22.31% |
2017 FY | 411.14 Million USD | 530.29% |
2017 Q4 | 411.14 Million USD | -13.57% |
2016 FY | 65.23 Million USD | 78.93% |
2016 Q4 | 65.23 Million USD | 7.59% |
2016 Q3 | 60.63 Million USD | 69.82% |
2016 Q2 | 35.7 Million USD | -3.34% |
2016 Q1 | 36.93 Million USD | 1.31% |
2015 Q3 | 32.44 Million USD | 23.64% |
2015 Q2 | 26.24 Million USD | 6.02% |
2015 Q4 | 36.45 Million USD | 12.36% |
2015 FY | 36.45 Million USD | 47.95% |
2015 Q1 | 24.75 Million USD | 0.45% |
2014 Q4 | 24.64 Million USD | 0.0% |
2014 FY | 24.64 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 58.721% |
PainReform Ltd. | 2.69 Million USD | -1999.554% |
Alvotech | 1.88 Billion USD | 96.999% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 94.039% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 88.022% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 65.529% |
Dynavax Technologies Corporation | 375.02 Million USD | 84.935% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 91.45% |
Bright Green Corporation | 6.43 Million USD | -777.572% |
Pacira BioSciences, Inc. | 704.25 Million USD | 91.977% |
Embecta Corp. | 2.03 Billion USD | 97.225% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -820.239% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -820.239% |
SCYNEXIS, Inc. | 55.45 Million USD | -1.892% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -165.057% |
Silver Spike Investment Corp. | 3 Million USD | -1777.149% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -514.346% |
Alpha Teknova, Inc. | 38.55 Million USD | -46.557% |
Safety Shot Inc | 3.89 Million USD | -1351.654% |
Procaps Group, S.A. | 462.06 Million USD | 87.772% |
Cosmos Health Inc. | 30.25 Million USD | -86.758% |
Theratechnologies Inc. | 98.63 Million USD | 42.721% |
Harrow Health, Inc. | 241.75 Million USD | 76.629% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -545.26% |
Biofrontera Inc. | 23.13 Million USD | -144.172% |
DURECT Corporation | 30.4 Million USD | -85.815% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 88.41% |
Cronos Group Inc. | 43.73 Million USD | -29.182% |
OptiNose, Inc. | 194.33 Million USD | 70.927% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 93.088% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -16.625% |
RedHill Biopharma Ltd. | 20.97 Million USD | -169.323% |
Organogenesis Holdings Inc. | 181.36 Million USD | 68.847% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -1397.799% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -7.584% |
Radius Health, Inc. | 804.29 Million USD | 92.975% |
Universe Pharmaceuticals INC | 13.75 Million USD | -310.772% |
ProPhase Labs, Inc. | 42.54 Million USD | -32.801% |
Phibro Animal Health Corporation | 725.54 Million USD | 92.213% |
Procaps Group S.A. | 462.06 Million USD | 87.772% |
TherapeuticsMD, Inc. | 14.02 Million USD | -302.931% |
Viatris Inc. | 27.21 Billion USD | 99.792% |
Rockwell Medical, Inc. | 30.88 Million USD | -82.951% |
Aytu BioPharma, Inc. | 90.37 Million USD | 37.487% |
SIGA Technologies, Inc. | 57.97 Million USD | 2.55% |
Tilray Brands, Inc. | 892.11 Million USD | 93.667% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 74.295% |
Shineco, Inc. | 47.6 Million USD | -18.691% |
PetIQ, Inc. | 645.22 Million USD | 91.244% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -25638.456% |
Incannex Healthcare Limited | 5.83 Million USD | -869.108% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 94.458% |
Alimera Sciences, Inc. | 107.35 Million USD | 47.371% |
Assertio Holdings, Inc. | 148.41 Million USD | 61.932% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2879.96% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -704.142% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -565.435% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 67.415% |
Hempacco Co., Inc. | 18.82 Million USD | -200.169% |
Talphera, Inc. | 6.29 Million USD | -798.235% |
Alvotech | 1.88 Billion USD | 96.999% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 67.266% |
Lantheus Holdings, Inc. | 835.25 Million USD | 93.236% |
Currenc Group, Inc. | 177.67 Million USD | 68.201% |
Kamada Ltd. | 109.96 Million USD | 48.622% |
Indivior PLC | 1.95 Billion USD | 97.104% |
Evoke Pharma, Inc. | 9.64 Million USD | -485.598% |
Flora Growth Corp. | 17.22 Million USD | -228.063% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -565.435% |
Evolus, Inc. | 209.68 Million USD | 73.056% |
HUTCHMED (China) Limited | 536.38 Million USD | 89.467% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 93.532% |
Akanda Corp. | 12.66 Million USD | -345.967% |